Disposition of [14C] ABT-199 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Following a Single Oral Dose Administration
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2014
Price : $35 *
At a glance
- Drugs Venetoclax (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors AbbVie
- 21 Nov 2014 Last checked against ClinicalTrials.gov record.
- 12 Aug 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 09 Jun 2014 Planned initiation date changed from 1 May 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.